Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canacardia: Canagliflozin in T2D and Heart Failure
NCT03298009Withdrawn
- Sponsor
- Université de Sherbrooke
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and heart failure (HF) comparing Placebo with Canagliflozin (2 arms). Primary endpoints: Myocardial dietary fatty acid uptake at 3 months and Whole-body partitioning of dietary fatty acids at 3 months. Planned start May 2018; status: withdrawn.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT03298009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298009.